340B Compliance and Optimization
Program reviews, HRSA audit readiness, and contract pharmacy oversight, led by an Apexus Advanced 340B Certified pharmacist who has run one of the larger 340B programs in the region and sat on the entity side of the table during audit.
The margin between the 340B price and what the payer actually reimburses.
Protected by compliance
Reinvested in charity care, clinical staff, and the patients the program was built for.
Engagements are scoped to entity type, size, and the specific exposure you are carrying. Covered entity or grantee, in-house or contract pharmacy.
A structured look at whether the program you are running is the program you are registered to run.
A mock audit against the current protocol, run the way an auditor would run it, before anyone else does.
Most leakage and most exposure live in the same place: the configuration nobody has reviewed since go-live.
Get the accumulator wrong and you lose on compliance and margin at the same time, and usually nobody notices until an audit or a bad quarter forces the question.
In most 340B programs, oncology and infusion carry the largest dollar volume, and that is also where capture most often breaks down.
What is leaking, what each gap costs on an annualized basis, and what it takes to close it.
Deliverables are short by design. The test is whether your team can run them after I leave.
Bring the audit finding, the number that is not adding up, or the workflow that keeps stalling. If I can help I will tell you how. If I cannot, I will point you to someone who can.